Search

Your search keyword '"HTLV-I Infections physiopathology"' showing total 135 results

Search Constraints

Start Over You searched for: Descriptor "HTLV-I Infections physiopathology" Remove constraint Descriptor: "HTLV-I Infections physiopathology"
135 results on '"HTLV-I Infections physiopathology"'

Search Results

1. Neurological aspects of HTLV-1 infection: symptoms in apparently asymptomatic carriers.

2. The relative contributions of infectious and mitotic spread to HTLV-1 persistence.

3. HTLV-I induces lesions in the pulmonary system: A systematic review.

4. Acupuncture in the treatment of HTLV-I-associated myelopathy / tropical spastic Paraparesis.

5. HTLV-1 bZIP factor: the key viral gene for pathogenesis.

6. Ocular vestibular evoked myogenic potential (VEMP) reveals mesencephalic HTLV-1-associated neurological disease.

7. Prevalence of Bowel Symptoms in Patients Infected with Human T-Lymphotropic type 1 Virus.

8. Different roles of CXCR1 and CXCR2 in HTLV-1 carriers and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients.

9. Balance Impairments in Patients with Human T-Cell Lymphotropic Virus Type 1 Infection.

10. Memory impairment: an intermediate clinical syndrome symptom in HTLV-1-infected patients?

11. Association between human T cell leukemia virus 1 (HTLV-1) infection and advanced periodontitis in relation to hematopoietic activity among elderly participants: a cross-sectional study.

12. HIV co-infection in HTLV-1 carriers in Spain.

13. HTLV-1 Tax-1 interacts with SNX27 to regulate cellular localization of the HTLV-1 receptor molecule, GLUT1.

14. Stability of the HTLV-1 glycoprotein 46 (gp46) gene in an endemic region of the Brazilian Amazon and the presence of a significant mutation (N93D) in symptomatic patients.

15. CT Chest and pulmonary functional changes in patients with HTLV-associated myelopathy in the Eastern Brazilian Amazon.

16. Isolated bladder dysfunction in human T lymphotropic virus type 1 infection: 10 years of follow-up.

17. Treatment of rheumatoid arthritis with biologics may exacerbate HTLV-1-associated conditions: A case report.

18. Quality of life and pain multidimensional aspects in individuals with HTLV-1.

19. Barefoot Plantar Pressure Indicates Progressive Neurological Damage in Patients with Human T-Cell Lymphotropic Virus Type 1 Infection.

20. Acetylation of the c-MYC oncoprotein is required for cooperation with the HTLV-1 p30(II) accessory protein and the induction of oncogenic cellular transformation by p30(II)/c-MYC.

21. HTLV-1 Tax-mediated inhibition of FOXO3a activity is critical for the persistence of terminally differentiated CD4+ T cells.

22. Effects of tDCS-induced motor cortex modulation on pain in HTLV-1: a blind randomized clinical trial.

23. Human T-lymphotropic virus type 1-infected cells secrete exosomes that contain Tax protein.

24. Adult T-cell leukemia/lymphoma.

25. HTLV-1 infects human mesenchymal stromal cell in vitro and modifies their phenotypic characteristics.

26. Resveratrol suppresses cell proliferation via inhibition of STAT3 phosphorylation and Mcl-1 and cIAP-2 expression in HTLV-1-infected T cells.

27. Association between urinary symptoms and quality of life in HTLV-1 infected subjects without myelopathy.

28. HTLV-1 bZIP factor induces inflammation through labile Foxp3 expression.

29. Major depression and generalized anxiety disorder among human T-lymphotropic virus types I- and II-infected former blood donors.

30. HTLV-1 tax-induced rapid senescence is driven by the transcriptional activity of NF-κB and depends on chronically activated IKKα and p65/RelA.

31. Correlation between LTR point mutations and proviral load levels among human T cell lymphotropic virus type 1 (HTLV-1) asymptomatic carriers.

32. Programmed death-1 (PD-1)/PD-1 ligand pathway-mediated immune responses against human T-lymphotropic virus type 1 (HTLV-1) in HTLV-1-associated myelopathy/tropical spastic paraparesis and carriers with autoimmune disorders.

33. Human T-lymphotropic virus 1 (HTLV-1) infection--dermatological implications.

34. Genomic instability and rapid clinical course in adult T-cell lymphoma/leukemia patient.

35. [A 52-year-old man with gait instability].

36. Changes in T cell phenotype and activated MAPKs are correlated to impaired cellular responses to antigens and glucocorticoids during HTLV-I infection.

38. Pearls & Oy-sters: "Not multiple sclerosis" and the changing face of HTLV-1: A case report of downbeat nystagmus.

39. Neurological aspects of HIV/human T lymphotropic virus coinfection.

40. [Immunopathogenesis and treatment of the myelopathy associated to the HTLV-I virus].

41. Adult T-cell leukemia/lymphoma in a patient from Romania: a case report and review of the literature.

42. The HTLV-1 Tax interactome.

43. Knockdown of synapse-associated protein Dlg1 reduces syncytium formation induced by human T-cell leukemia virus type 1.

44. Vestibular-evoked myogenic potential (VEMP) to evaluate cervical myelopathy in human T-cell lymphotropic virus type I infection.

45. [Neurological symptoms and disability in HTLV-1 associated myelopathy].

46. A novel bioluminescent mouse model and effective therapy for adult T-cell leukemia/lymphoma.

47. Ubiquitination of HTLV-I Tax in response to DNA damage regulates nuclear complex formation and nuclear export.

48. Upregulation of CC chemokine ligand 18 and downregulation of CX3C chemokine receptor 1 expression in human T-cell leukemia virus type 1-associated lymph node lesions: Results of chemokine and chemokine receptor DNA chip analysis.

49. Clinical manifestations of human T lymphotropic virus type I-infected patients with systemic lupus erythematosus.

50. Myasthenia gravis associated with HTLV-I infection and atypical brain lesions.

Catalog

Books, media, physical & digital resources